I-Mab Acquires Bridge Health to Boost Givastomig Portfolio

I-MAB ( (IMAB) ) has shared an update.

On July 17, 2025, I-Mab announced the acquisition of Bridge Health Biotech Co., Ltd., aiming to enhance its intellectual property portfolio for the bispecific antibody, givastomig. This strategic move is expected to eliminate royalty obligations, reduce future milestone payments, and strengthen I-Mab’s position in the immuno-oncology market. The acquisition, which includes an upfront payment of $1.8 million and additional non-contingent payments, is anticipated to close in the third quarter of 2025, potentially impacting future clinical developments and stakeholder interests.

The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

Spark’s Take on IMAB Stock

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

More about I-MAB

I-Mab is a U.S.-based, global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company’s leading product is givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers, with potential applications in other solid tumors.

Average Trading Volume: 544,677

Technical Sentiment Signal: Buy

Current Market Cap: $165.8M

For a thorough assessment of IMAB stock, go to TipRanks’ Stock Analysis page.